MultiDomeTM Platform

MultiDome™ – Multivalent and Multispecific VHH Antibody Platform

What is MultiDome™

MultiDome™ is our proprietary platform for designing multivalent and multispecific VHH antibody constructs, built on the same FC8™ scaffold framework that underlies every Cortalix VHH. By linking two, three, or more FC8™-derived VHH domains with carefully selected linkers, either flexible or more rigid, we create constructs that maintain all the inherent advantages of monovalent VHHs, while offering entirely new functional opportunities.

Unlike scFv fragments, which often retain hydrophobic patches that make them unstable and more difficult to express, MultiDome™ constructs are highly soluble, stable, and easy to produce. This makes them a superior choice for therapeutic and diagnostic applications where stability and scalability are critical.

How it Works

MultiDome™ allows the modular assembly of VHH antibody domains in different architectures:

  • Bi- or tri-specific constructs: simultaneously targeting two or three different proteins.

  • Multi-epitope constructs: recognizing distinct epitopes on the same protein, enhancing avidity and functional activity.

  • Valency tuning: engaging the same epitope on multiple molecules of a target protein to boost binding strength.

The choice of linker, flexible or rigid, short or extended, determines how the VHH domains interact structurally and functionally. This flexibility allows for optimal construct design tailored to the biology of the target.

Figure: Examples of multivalent and multispecific VHH antibody constructs. Individual VHH domains can be linked flexibly or rigidly to form bi- or tri-valent molecules, or combined to generate bispecific and trispecific formats. Target-binding VHH antibodies (green, pink) can be combined with albumin-binding VHH antibodies (blue) to optimize pharmacokinetics while retaining the inherent stability and solubility of monovalent VHH antibodies.

Framework Quality: Built on FC8TM

Every VHH antibody scaffold within the MultiDomeTM platform is built on our proprietary FC8TM framework, engineered from the outset to be >90% humanized, minimizing the risk of immunogenicity. FC8TM is also free of liability sites that could otherwise result in unwanted post-translational modifications. This ensures stable, safe, and translationally relevant constructs for therapeutic development, whether the individual VHH domains originate from FC8TM synthetic discovery or from immune libraries grafted onto the FC8TM framework.

Advantages of MultiDome™

  • Retains all benefits of monovalent VHH antibodies: small size, high stability, easy expression.
  • Superior stability compared to scFv or Fab fragments.
  • Modular design with flexible or rigid linkers for tailored geometry.
  • Humanized, liability-free FC8TM scaffolds for low immunogenicity.
  • Applicable to oncology, immunotherapy, and radiopharmaceuticals

Applications

  • Oncology: dual targeting of tumor antigens to improve efficacy.

  • Radiopharmaceuticals: tri-specific tracers combining two cancer targets with an albumin-binding domain from our AlbuFlex™ platform, for optimized PK.

  • Inflammation and fibrosis: multi-epitope constructs to increase potency and selectivity.

Our approach

At Cortalix, we systematically design and test MultiDome™ architectures, adjusting valency, epitope targeting, and linker flexibility. Every building block starts from our FC8TM Discovery Platform, ribosomal display and phage display, or immune libraries grafted onto the FC8TM framework, so construct design and binder discovery stay tightly integrated. In collaboration with partners, we develop constructs that translate into more effective therapies and diagnostics.

Select Source

  • Jovčevska I, Muyldermans S. The Therapeutic Potential of Nanobodies. BioDrugs. 2020;34:11-26. doi:10.1007/s40259-019-00392-8.

  • Steeland S, Vandenbroucke RE, Libert C. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today. 2016;21(7):1076-1113. doi:10.1016/j.drudis.2016.04.003.

  • Van Audenhove I, Gettemans J. Nanobodies as Versatile Tools in Inflammation Research and Therapy. Front Immunol. 2016;7:407. doi:10.3389/fimmu.2016.00407.

  • Harmsen MM, Ackerschott B, de Smit H, et al. Serum immunoglobulin or albumin binding single-domain antibodies that enable tailored half-life extension of biologics in multiple animal species. Front Immunol. 2024;15:1346328. doi:10.3389/fimmu.2024.1346328.

  • Van Lith SAM, et al. Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging. Mol Pharmaceut. 2022;19(7):2192-2205. doi:10.1021/acs.molpharmaceut.1c00841.